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Abstract
Introduction: The objective of this study is to determine if multiple systemic autoimmune diseases (SAID) share
gene expression pathways that could provide insights into pathogenic mechanisms common to these disorders.
Methods: RNA microarray analyses (Agilent Human 1A(V2) 20K oligo arrays) were used to quantify gene expression
in peripheral blood cells from 20 monozygotic (MZ) twin pairs discordant for SAID. Six affected probands with
systemic lupus erythematosus (SLE), six with rheumatoid arthritis (RA), eight with idiopathic inflammatory
myopathies (IIM), and their same-gendered unaffected twins, were enrolled. Comparisons were made between
discordant twin pairs and these were also each compared to 40 unrelated control subjects (matched 2:1 to each
twin by age, gender and ethnicity) using statistical and molecular pathway analyses. Relative quantitative PCR was
used to verify independently measures of differential gene expression assessed by microarray analysis.
Results: Probands and unrelated, matched controls differed significantly in gene expression for 104 probes
corresponding to 92 identifiable genes (multiple-comparison adjusted P values < 0.1). Differentially expressed genes
involved several overlapping pathways including immune responses (16%), signaling pathways (24%), transcription/
translation regulators (26%), and metabolic functions (15%). Interferon (IFN)-response genes (IFI27, OASF, PLSCR1,
EIF2AK2, TNFAIP6, and TNFSF10) were up-regulated in probands compared to unrelated controls. Many of the
abnormally expressed genes played regulatory roles in multiple cellular pathways. We did not detect any probes
expressed differentially in comparisons among the three SAID phenotypes. Similarly, we found no significant
differences in gene expression when comparing probands to unaffected twins or unaffected twins to unrelated
controls. Gene expression levels for unaffected twins appeared intermediate between that of probands and
unrelated controls for 6535 probes (32% of the total probes) as would be expected by chance. By contrast, in
unaffected twins intermediate ordering was observed for 84 of the 104 probes (81%) whose expression differed
significantly between probands and unrelated controls.
Conclusions: Alterations in expression of a limited number of genes may influence the dysregulation of numerous,
integrated immune response, cell signaling and regulatory pathways that are common to a number of SAID. Gene
expression profiles in peripheral blood suggest that for genes in these critical pathways, unaffected twins may be
in a transitional or intermediate state of immune dysregulation between twins with SAID and unrelated controls,
perhaps predisposing them to the development of SAID given the necessary and sufficient environmental
exposures.
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Introduction
Previous studies suggest that patterns of gene expression
as measured by RNA microarray are correlated among
healthy twins, siblings, and other first-degree family
members [1-3]. These data support the importance of
shared genetic and perhaps environmental influences on
transcription and other controls of steady-state mRNA
expression. Interestingly, similar profiles of global RNA
expression are observed among first-degree family mem-
bers discordant for autoimmune disease, suggesting that
other healthy, first-degree relatives may have an under-
lying genetic predisposition to disease [2,4,5].
Shared patterns of global gene expression have also
been observed among genetically unrelated individuals
with systemic autoimmune diseases (SAIDs), including
systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) [6-9]. These data support the hypothesis
that different autoimmune diseases share certain clinical
features and perhaps mechanisms of disease pathogen-
esis. Most notably, the type I IFN ‘signature’ associated
with the transcriptional control of many IFN-regulated
gene products has been consistently detected among
patients with SLE, dermatomyositis (DM), or other
SAIDs [8,10-16]. Conversely, disease-specific gene
expression profiles are associated with particular auto-
immune pathologies and may reflect target tissue speci-
ficity and other distinctions in genetic susceptibilities or
environmental exposure histories or both [7,17-20].
To minimize the role of polymorphic gene effects, we
enrolled 20 pairs of monozygotic (MZ) twins discordant
for SAID (six probands with SLE, six with RA, and eight
with idiopathic inflammatory myopathies, or IIMs) and
used RNA microarrays (Agilent Human 1A(V2); 20K) to
examine gene expression patterns in their peripheral
blood cells. To determine whether unaffected twins
might show preclinical evidence of enhanced susceptibil-
ity to SAID, we also compared probands and their unaf-
fected twins with 40 unrelated, matched control subjects.
One might expect etiologically relevant genes to show
expression patterns in the unaffected twins that are inter-
mediate between those in their affected twin counterparts
and in unrelated, matched controls. Moreover, in an
effort to identify shared molecular pathways involved in
the pathogenesis of these SAIDs, we asked whether parti-
cular gene expression profiles were characteristic of
affected probands regardless of specific disease diagnosis.
Materials and methods
Study subjects
Five adult (at least 18 years of age) and 15 juvenile MZ
twin pairs discordant for SAID and 40 unrelated control
subjects (two controls per twin pair) matched on age
within 6 years, gender, and ethnicity were subjects in
this study. These subjects were among those enrolled
between 2001 and 2006 in the National Institutes of
Health (NIH) investigational review board-approved
Twins-Sib study assessing the pathogenesis of SAID.
Ethical approval for this microarray study was also
obtained from the NIH investigational review board, and
all human subjects provided informed consent. Twin
pairs enrolled within 4 years of probands’ diagnoses
included 19 non-Hispanic Caucasian twin pairs and a
single Hispanic twin pair (with SLE). Probands fulfilled
American College of Rheumatology criteria for adult or
juvenile SLE (n = 4 and 2, respectively), RA or JRA (n =
1 and 5, respectively), juvenile dermatomyositis (JDM)
(n = 7), or juvenile polymyositis (JPM) (n = 1); we
excluded patients with inherited, metabolic, infectious,
or other causes of disease. The juvenile probands ranged
in age from 3 to 18 years (mean of 11.2 years), whereas
adults ranged from 19 to 43 years (mean of 29.2 years).
Twins included 14 female and 6 male pairs. Monozygos-
ity was confirmed by short tandem repeat analysis of
genomic DNAs (Proactive Genetics, Inc., Augusta, GA,
USA). Unrelated, matched controls were free of infec-
tions, trauma, vaccines, and surgeries for 8 weeks and
had no first-degree family members with SAID.
RNA was purified from peripheral whole blood sam-
ples collected in PAXgene RNA tubes (VWR Scientific,
Radnor, PA, USA) by using a PAXgene RNA Isolation
Kit (Qiagen, Inc., Valencia, CA, USA) in accordance
with the recommendations of the manufacturer. Total
RNA was quantified spectrophotometrically and then
stored at -80°C until analysis. To minimize sources of
variability, we collected whole blood samples in the
morning, and immunosuppressive therapy was held at
least 24 hours before collection.
Microarray analysis
Gene expression analysis was conducted by using Agi-
lent Human 1A(V2) Oligo arrays with approximately
20,000 probes for known genes and expressed sequence
tags (Agilent Technologies, Inc., Santa Clara, CA, USA).
Each sample was hybridized against a human universal
RNA control (Stratagene, La Jolla, CA, USA). Total
RNA (500 ng) was amplified and labeled by using the
Agilent Low RNA Input Fluorescent Linear Amplifica-
tion Kit in accordance with the protocol of the manu-
facturer. For each two-color comparison, 750 ng of each
Cy3- (universal control) and Cy5-labeled sample cRNA
was mixed and fragmented by using the Agilent in situ
Hybridization Kit. Hybridizations were performed for 17
hours in a rotating hybridization oven. Slides were
washed and then scanned with an Agilent scanner. Data
were obtained by using Agilent Feature Extraction soft-
ware (version 7.5), with defaults for all parameters. The
Agilent Feature Extraction Software performed error
modeling, adjusting for additive and multiplicative noise.
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The resulting data were processed by using the Rosetta
Resolver system (version 7.2) (Rosetta Biosoftware, now
part of Microsoft Corporation, Redmond, WA, USA).
Resulting base 2 logarithms of expression ratios (subject
over universal control) were exported from Rosetta
Resolver for further analysis. The data reported in this
publication have been deposited in the National Center
for Biotechnology Information’s Gene Expression Omni-
bus (GEO) [21] and are accessible through GEO Series
accession number [GEO:GSE24060].
Microarray data normalization and quality control
We used principal component analysis (PCA) to investi-
gate the effect of known sample variables such as sub-
ject age, gender, race, disease status, disease activity,
medications, and peripheral white blood cell counts and
differentials as well as technical variables such as sample
hybridizations performed at different times. We
observed no obvious differences across the first three
principal components due to age, gender, ethnicity, dis-
ease status, disease activity, or treatment. We noticed,
however, that samples clustered according to their
hybridization batch. To correct for this, we centered the
ratios for each probe by using the median for their
hybridization group. The PCA plots generated by using
the corrected data showed no obvious groupings, so we
used these data for further analyses.
Identification of differentially expressed probes
To identify probes that were differentially expressed in
probands (P) as compared with their unaffected twin
(U) and with unrelated, matched controls (C), we
employed a mixed-effects model to calculate P values
for each of the approximately 20,000 probes. Random
effects included indicators for twin pairs, for P-versus-U
comparisons, and for the strata defined by the matching
variables for the P-versus-C and U-versus-C compari-
sons. With these adjustments, we performed three bin-
ary comparisons: (a) P versus C, in which all probands
with SAID were compared with two unrelated, matched
controls; (b) U versus C, in which all unaffected twins
were compared with two unrelated, matched controls;
(c) P versus U, in which all probands with SAID were
compared with their unaffected twins in a paired analy-
sis. We adjusted P values from each of the above three
comparisons to control the false discovery rate (FDR) at
0.1 by using the Benjamini-Hochberg method [22].
Disease-specific gene expression analyses
The goal was to investigate whether blood cell gene
expression profiles for probands with SAID - namely (J)
RA, (J)SLE, and (J)IIM (that is, JDM + JPM) - show
characteristic differences in gene expression. To answer
this question, we used all probe expression data and
employed three different types of statistical analyses: (a)
Hierarchical clustering - we performed unsupervised
hierarchical clustering by using all 20 proband samples
to check whether probands cluster by their known SAID
subtype. (b) Multiclass analysis of variance (ANOVA) -
to assess whether the difference between the gene
expression of a proband and their respective twin is
SAID subtype-specific, we first obtained a measurement
of the gene expression difference per twin pair for each
probe by subtracting the log-transformed expression
value of the unaffected twin from that of the respective
affected twin. We next grouped twin pairs into the three
major SAID diagnostic classes. Finally, we performed a
three-category, one-way ANOVA by using the differ-
ences in log-transformed expression values for each
oligo probe. The P values were then adjusted for multi-
ple testing by using the Benjamini-Hochberg method
with the FDR of 0.1 [22]. (c) Mixed-effects model - to
assess whether the difference between the gene expres-
sion of an affected proband and their corresponding
unrelated but matched controls is SAID subtype-speci-
fic, we employed a mixed-effects model allowing a ran-
dom effect for each matched set and treating the disease
subtype as a fixed effect. The P values were then
adjusted for multiple testing by using the Benjamini-
Hochberg method with the FDR of 0.1 [22].
Functional analysis of differentially expressed genes
We used Ingenuity Pathways Analysis (IPA) software
(Ingenuity® Systems, Redwood City, CA, USA) to assess
functional class membership for probes identified as dif-
ferentially expressed between probands and unrelated,
matched controls. Each gene of interest was mapped
and overlaid onto a global molecular network developed
from information contained in the IPA Knowledge Base.
Networks of genes were then generated algorithmically
on the basis of their connectivity as established in the
published literature. Fisher’s exact test was used to
assess whether the number of probes mapped to each
biologic function or pathway (or both) differs from the
number expected due to chance alone.
Real-time polymerase chain reaction analysis
Relative quantitation (RQ) measurements of gene
expression were by real-time polymerase chain reaction
(RT-PCR) assays using cDNA prepared from Paxgene-
purified whole peripheral blood RNA preparations col-
lected from disease-discordant twins and unrelated,
matched controls as described above. cDNA was pre-
pared by using a High Capacity cDNA Reverse Tran-
scription kit (1.0 μg of input RNA per subject) in
accordance with the recommendations of the manufac-
turer (Applied Biosystems, Foster City, CA, USA). RT-
PCRs were performed in triplicate by using
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commercially prepared cDNA primers and probes (Taq-
Man Gene Expression Assays; Applied Biosystems) for
the following genes of interest: MAP2K6 (TaqMan
Assay Hs00992389), IL1RN (Hs00893626), IFI27
(Hs00271467), FCER1A (Hs01090134), FYN
(Hs00176628), LTK (Hs00914334), KRTCAP2
(Hs00744717), SYTL2 (Hs00262988), ANXA3
(Hs00971411), CEACAM6 (Hs00366002), DEFA4
(Hs00157252), TNFAIP6 (Hs01113602), TNFSF10
(Hs00234356), EIF2AK2 (Hs00169345), and LGR6
(Hs00663887). Genes of interest were selected from the
microarray analysis by a combination of criteria, includ-
ing degree of statistical significance, magnitude of differ-
ential gene expression, and possible biologic relevance
to disease. Standard TaqMan assays (20 μL) were per-
formed by using an Applied Biosystems Universal Assay
Buffer with 10 ng of input cDNA per reaction and
amplified for 40 cycles in an ABI Prism 7900HT
Sequence Detection System (SDS software version 2.3).
Co-amplication of human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) served as an endogenous assay
and standardization control. RQ of gene expression was
calculated from log-phase mean threshold cycle values
normalized to GAPDH expression by using Applied Bio-
systems RQ Manager software (version 1.2).
Results
Microarray differential expression analysis
Significant differences (FDR-adjusted P values of less
than 0.1) were observed for 104 oligo probes in analyses
of SAID probands compared with the unrelated,
matched controls (Table 1). Upon probe annotation, 92
genes representing several non-mutually exclusive cate-
gories, including immune function (16%), signaling path-
ways (24%), transcription/translation regulators (26%),
and metabolic functions (15%), were identified (Table 2).
Of these 92 genes, 73.9% were underexpressed (mean
fold change of 0.71 and range of 0.91 to 0.56) and 26.1%
were overexpressed (mean fold change of 2.2 and range
of 1.1 to 7.2) in probands relative to unrelated, matched
controls.
Comparisons between probands with SAID and their
unaffected twins produced no significant differences in
gene expression values (that is, the smallest adjusted P
values were greater than 0.1), although several of the
top-ranking genes were shared with those identified as
significant in comparisons of probands and unrelated,
matched controls. Comparisons of unaffected twins and
unrelated, matched controls likewise revealed no signifi-
cant differences in gene expression.
We conducted an unsupervised, hierarchical cluster
analysis for all 80 subjects (20 probands, 20 unaffected
twins, and 40 unrelated, matched controls) by using the
expression data for the 104 probes with significant
differential expression on the basis of the comparison of
probands versus unrelated controls. The resulting heat
map (Figure 1) demonstrated a clear segregation of the
probands with SAID and the unrelated, matched con-
trols. In contrast, the unaffected twins were interspersed
among and between the probands and unrelated con-
trols. The first two major branches of the dendrogram
divided the heat map into approximately equal numbers
of study subjects (that is, 40 in the top half and 40 in
the bottom half of the heat map). While all probands
segregate into the top half of the map (that is, Figure 1,
branch 1), the unaffected twins were equally distributed
between the two major branches. The unrelated,
matched controls were distributed between the two
major branches (approximately 1/3 in branch 1 and 2/3
in branch 2). We also observed that several probands
mapped outside the primary proband cluster (branch 1).
Further analyses of proband outliers did not reveal any
significant differences in age, medications, disease dura-
tion, physical exam findings, patient- and physician-
assessed levels of disease activity, white blood or platelet
counts, or hematocrit when compared with probands in
the primary cluster (data not shown).
A PCA of the 80 study subjects by using the same 104
differentially expressed probes again revealed segrega-
tion of probands from unaffected twins and unrelated,
matched controls (Figure 2). No differences due to age,
gender, ethnicity, disease status, or treatment were
observed across the first three principal components.
While the distinction between unaffected twins and
unrelated, matched controls was less obvious in this
PCA, our inability to detect any significant differences
in gene expression between unaffected twins and either
probands or unrelated, matched controls suggested that
the gene expression profile of unaffected twins may sig-
nify an intermediate or transitional state between the
healthy and disease phenotypes. We observed further
that the average gene expression for unaffected twins
was intermediate between that of twins with SAID and
unrelated, matched controls for 6,535 (32%) of a total of
approximately 20,000 probes on the chip (about one
third of all probes might be predicted to show this pat-
tern by chance alone). By contrast, the same intermedi-
ate ordering was observed for 84 out of 104 probes
(81%) that were significantly different between probands
and controls.
Disease subtypes
By performing an unsupervised hierarchical clustering of
all proband samples, we further examined whether pro-
bands might also segregate by disease subtype (that is,
SLE, RA, and IIM). The clustering did not segregate
probands into groups dominated by SAID subtypes
(data not shown). Second, to identify probes that were
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Table 1 Genes that were differentially expressed between probands (n = 20) with systemic autoimmune disease and
unrelated, matched controls (n = 40)
Accession Annotation Fold
changea
P valueb FDR Function/Category
Increased expression in
probands
TNFAIP6 Tumor necrosis factor-alpha-induced protein 6 2.2 1.5 × 10-5 0.051 Co-factor, immune
HP Haptoglobin 2.2 2.0 × 10-5 0.051 Carrier, transport
HPR Haptoglobin-related protein 2.3 3.5 × 10-5 0.059 Carrier, transport
ANXA3 Annexin A3 2.8 5.1 × 10-5 0.074 Regulation, signaling
APOBEC3A Apolipoprotein B mRNA editing enzyme 3A 1.4 5.8 × 10-5 0.074 Regulation, translation
EIF2AK2 Eukaryotic translation initiation factor 2-alpha
kinase 2
2.4 7.1 × 10-5 0.074 Regulation, translation
BMX Non-receptor tyrosine kinase 2.2 8.6 × 10-5 0.074 Kinase, signaling
CEACAM6 Carcinoembryonic Ag-related cell adhesion
molecule 6
4.7 8.7 × 10-5 0.074 Receptor, targeting
PLSCR1 Phospholipid scramblase 1 2.3 1.0 × 10-4 0.074 Regulation, immune
LTF Lactotransferrin 2.3 1.1 × 10-4 0.074 Regulation, immune
TNFSF10 Tumor necrosis factor ligand 10 1.6 1.4 × 10-4 0.074 Cytokine, immune
OASL 2’-5’-Oligoadenylate synthetase-like 2.2 1.7 × 10-4 0.074 Binding, thyroid receptor
MAP2K6 Mitogen-activated protein kinase kinase 6 1.4 2.2 × 10-4 0.080 Kinase, signaling
ZCCHC2 Zinc finger protein 1.5 2.4 × 10-4 0.082 Unknown, signaling
INHBB Inhibin, beta B 2.3 2.7 × 10-4 0.085 Ligand, signaling
DEFA4 Defensin, alpha 4, corticostatin 2.3 2.9 × 10-4 0.088 Ligand, signaling
IFI27 Interferon, alpha-inducible protein 27 7.2 3.0 × 10-4 0.088 Unknown, immune
SLC22A4 Solute carrier family 22, member 4 1.7 3.3 × 10-4 0.088 Transport
IL1RN Interleukin 1 receptor antagonist 1.7 3.4 × 10-4 0.088 Ligand, immune
RRAGD Ras-related GTP-binding protein D 1.3 3.4 × 10-4 0.088 Ligand, signaling
DEGS1 Degenerative spermatocyte homolog 1 1.1 3.9 × 10-4 0.093 Enzyme, metabolism
PGAP1 GPI deacylase 1.3 3.9 × 10-4 0.093 Enzyme, signaling
F5 Coagulation factor V 1.4 4.2 × 10-4 0.094 Ligand, coagulation
CDS2 CDP-diacylglycerol synthase 1.2 4.6 × 10-4 0.097 Enzyme, metabolism
HIST1H2AB Histone 1, H2ab 1.3 4.7 × 10-4 0.097 Chromatin, structural
Decreased expression in
probands
PACSIN1 Protein kinase C substrate 1 in neurons -1.4 3.3 × 10-6 0.042 Kinase, signaling
KRTCAP2 Keratinocyte-associated protein 2 -1.2 5.9 × 10-6 0.042 Enzyme, structural
FCER1A Fc fragment of high affinity IgE receptor -1.9 9.2 × 10-6 0.042 Receptor, immune
FYN Oncogene -1.3 9.8 × 10-6 0.042 Kinase, signaling
SYTL2 Synaptotagmin-like 2 -1.5 1.0 × 10-5 0.042 Unknown, immune
CD99 MIC2, single-chain type-1 glycoprotein -1.2 1.8 × 10-5 0.051 Receptor, immune
PECI Peroxisomal D3,D2-enoyl-CoA isomerase -1.3 3.3 × 10-5 0.059 Enzyme, metabolism
CD81 Target of antiproliferative antibody 1 -1.2 3.4 × 10-5 0.059 Receptor, immune
PBX4 Pre-B-cell leukemia transcription factor 4 -1.4 7.7 × 10-5 0.074 Regulation, transcription
DYRK2 Tyrosine-phosphorylation regulated kinase 2 -1.2 8.1 × 10-5 0.074 Kinase, signaling
ZBTB5 Zinc finger and BTB domain containing 5 -1.2 9.4 × 10-5 0.074 Regulation, transcription
PABPC3 Poly(A)-binding protein 3 -1.3 9.8 × 10-5 0.074 Regulation, translation
NELL2 NEL-like 2 -1.3 1.0 × 10-4 0.074 Mitogen, cell division
LOC100133315 Unknown cation channel/receptor -1.2 1.0 × 10-4 0.074 Receptor, signaling
DNAJA3 DnaJ (Hsp40) homolog A3 -1.3 1.2 × 10-4 0.074 Chaperone, transport
EIF3S6IP Eukaryotic translation initiation factor 3, subunit 6 -1.3 1.2 × 10-4 0.074 Regulation, translation
EIF3S8 Eukaryotic translation initiation factor 3, subunit 8 -1.2 1.2 × 10-4 0.074 Regulation, translation
RBMX RNA-binding motif protein -1.1 1.2 × 10-4 0.074 Regulation, transcription
GZMK Granzyme K -1.4 1.3 × 10-4 0.074 Enzyme, immune
DNMT1 DNA (cytosine 5)-methyltransferase 1 -1.3 1.3 × 10-4 0.074 Enzyme, metabolism
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Table 1 Genes that were differentially expressed between probands (n = 20) with systemic autoimmune disease and
unrelated, matched controls (n = 40) (Continued)
ZNF219 Zinc finger protein 219 -1.2 1.3 × 10-4 0.074 Regulation, transcription
DVL1 Dishevelled homologue (Drosophila) -1.2 1.4 × 10-4 0.074 Mitosis, signaling
IMP3 U3 small ribonucleoprotein homologue (yeast) -1.2 1.5 × 10-4 0.074 Structural, translation
ANAPC5 Anaphase promoting complex subunit 5 -1.2 1.5 × 10-4 0.074 Enzyme, cell cycle
AOF2 Amine oxidase (flavin containing) domain 2 -1.2 1.6 × 10-4 0.074 Regulation, transcription
GPRASP1 G protein-coupled receptor -1.4 1.6 × 10-4 0.074 Receptor, signaling
LTK Leukocyte tyrosine kinase -1.3 1.6 × 10-4 0.074 Kinase, immune
MTA1 Metastasis-associated 1 -1.2 1.6 × 10-4 0.074 Regulation, transcription
UXT Ubiquitously expressed transcript -1.2 1.6 × 10-4 0.074 Regulation, transcription
KLRB1 Killer cell lectin-like receptor B1 -1.6 1.7 × 10-4 0.074 Receptor, immune
SEMA4C Semaphorin 4C -1.3 1.7 × 10-4 0.074 Neural development
STMN3 Stathmin-like 3 -1.4 2.0 × 10-4 0.079 Cytoskeletal, signaling
ATP1A1 ATPase Na+/K+ transporter -1.2 2.0 × 10-4 0.079 Transporter, signaling
PSBP Prostatic steroid-binding protein -1.3 2.2 × 10-4 0.080 Receptor, signaling
RPL18 Ribosomal protein L18 -1.3 2.2 × 10-4 0.080 Structural, translation
RNF220 Ring finger protein -1.1 2.2 × 10-4 0.080 Unknown
SPOCK2 Sparc/osteonectin/proteoglycan (testican) 2 -1.2 2.3 × 10-4 0.081 Extracellular, structural
DDX28 DEAD box polypeptide -1.2 2.3 × 10-4 0.081 RNA helicase,
transcription
SRP46 Splicing factor, arginine/serine-rich, 46 kDa -1.3 2.4 × 10-4 0.082 Regulation, transcription
EIF3S7 Eukaryotic translation initiation factor 3S7 -1.2 2.5 × 10-4 0.084 Regulation, translation
TNFRSF25 Tumor necrosis factor receptor 25 -1.3 2.6 × 10-4 0.085 Receptor, immune
MYBL1 v-Myb myeloblastosis viral oncogene homolog -1.4 2.7 × 10-4 0.085 Regulation, transcription
UBE2I Ubiquitin-conjugating enzyme E2I -1.1 2.8 × 10-4 0.087 Enzyme, regulation
PABPC1 Poly(A)-binding protein -1.3 3.0 × 10-4 0.088 Regulation, translation
LDOC1L Leucine zipper, downregulated in cancer 1-like -1.4 3.1 × 10-4 0.088 Unknown
LGR6 Leucine-rich repeat-containing G protein receptor 6 -1.6 3.1 × 10-4 0.088 Receptor, signaling
AES Amino-terminal enhancer of split -1.1 3.2 × 10-4 0.088 Regulation, transcription
CXCR3 Chemokine receptor 3 -1.3 3.2 × 10-4 0.088 Receptor, immune
ATP5G2 ATP synthase, mitochondrial F0 complex -1.2 3.3 × 10-4 0.088 Enzyme, metabolism
RPLP2 Ribosomal protein P2 -1.3 3.3 × 10-4 0.088 Structural, translation
TC2N Membrane targeting C2 domain -1.4 3.6 × 10-4 0.090 Unknown, signaling
ERGIC3 Breast cancer antigen 84 -1.2 3.8 × 10-4 0.092 Unknown, cell growth
GPR183 Epstein-Barr virus induced gene 2 -1.5 3.9 × 10-4 0.093 Receptor, signaling
CSNK1E Casein kinase 1, epsilon -1.2 4.1 × 10-4 0.094 Kinase, regulation
CRIP1 Cysteine-rich protein 1 -1.3 4.1 × 10-4 0.094 Zn-binding, transport
ARIH2 Ariadne homolog 2 -1.1 4.2 × 10-4 0.094 Ubiquitin ligase,
regulation
POLS DNA polymerase sigma -1.2 4.2 × 10-4 0.094 Enzyme, metabolism
PUF60 Ro-RNP-binding protein -1.2 4.3 × 10-4 0.096 RNP-binding, regulation
MFNG Fucose-specific b-1,3-N-
acetylglucosaminyltransferase
-1.2 4.7 × 10-4 0.097 Enzyme, development
PRPSAP2 Phosphoribosyl pyrophosphate synthetase protein
2
-1.2 4.7 × 10-4 0.097 Enzyme, metabolism
STAG3 Stromal antigen 3 -1.3 4.7 × 10-4 0.097 Cohesion subunit,
meiosis
FBL Fibrillarin -1.2 4.9 × 10-4 0.098 snRNP-binding, pre-rRNA
RPS19 Ribosomal protein S19 -1.3 4.9 × 10-4 0.098 Structural, translation
DDB1 Damage-specific DNA-binding protein 1 -1.2 5.0 × 10-4 0.098 DNA repair
FBXO21 F-box protein 21 -1.2 5.0 × 10-4 0.098 Ubiquitin ligase,
regulation
PTDSS1 Phosphatidylserine synthase 1 -1.2 5.1 × 10-4 0.100 Enzyme, metabolism
AKR1B1 Aldo-keto reductase family 1, member B1 -1.2 5.2 × 10-4 0.100 Enzyme, metabolism
aFold change values indicate increased (positive value) or decreased (negative value) levels of gene expression in probands relative to unrelated, matched
controls. Oligo probes for hypothetical or unidentified genes were omitted. bUncorrected. FDR, false discovery rate.
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significantly different among the disease groups, for each
probe and each twin pair we calculated differences in
log-transformed gene expression levels between unaf-
fected and affected twins and compared these differ-
ences among disease groups with ANOVA. After
adjustments for multiple testing, we did not detect any
probes with significant P values among twin pairs whose
probands had different diagnoses (data not shown).
To further assess these findings, we employed a
mixed-effects model comparing probe expression values
from probands and unrelated, matched controls, strati-
fied by including a random effect for the matched sets,
and comparing across disease phenotypes. Again, after
adjustments for multiple testing, no significant differ-
ences in the change in gene expression (that is, the
fixed-effects interaction between disease status and phe-
notype category) were observed. Together, these data
suggest that either our disease-specific sample sizes
were too small to detect significant differences or
patients with different SAIDs possess similar gene
expression patterns.
Pathway analysis
To examine the possible functional clustering of genes
that were differentially expressed in SAID, we performed
IPAs to assess whether differentially expressed genes
might be linked by common biologic pathways. As
shown in Figure 3, those findings having the greatest
significance (that is, lowest P values) included several
canonical biologic pathways involved in immune
response and inflammation (signaling molecules for NF-
B, IL-6, FcεRI, Toll-like receptor signaling, apoptotic,
and acute-phase responses). In some instances, genes
expressed differentially in SAID were found to play a
regulatory role in multiple immune response and
inflammatory pathways. For example, mitogen-activated
protein kinase kinase 6 (MAP2K6) plays a regulatory
role in NF-B, IL-6, FcεRI, Toll-like receptor, and
acute-phase response pathways. Similarly, the interleukin
1 receptor antagonist (IL1RN) influences the NF-B, IL-
6, and acute-phase response pathways, and eukaryotic
translation initiation factor 2-alpha kinase 2 (EIF2AK2)
is likewise involved in NF-B and Toll-like receptor
Table 2 Functional categorization of genes differentially expressed between SAID probands and unrelated, matched
controls
Immune Signaling Gene expression Metabolism Transport Structural Cell cycle Other/Unknown
TNFAIP6 ANXA3 EIF2AK2 DEGS1 HP HIST1H2AB NELL2 ZCCHC2
PLSCR1 APOBEC3A PBX4 CDS2 HPR KRTCAP2 DVL1 RNF220
LTF BMX ZBTB5 PECI SLC22A4 SPOCK2 ANAPC5 LDOC1L
TNFSF10 CEACAM6 PABPC3 DNMT1 DNAJA3 SEMA4C DDB1
IFI27 OASL EIF3S6IP ATP5G2 CRIP1 ERGIC3
IL1RN MAP2K6 EIF3S8 POLS STAG3
FCER1A INHBB RBMX MFNG
SYTL2 DEFA4 ZNF219 PRPSAP2
CD99 RRAGD IMP3 PTDSS1
CD81 PGAP1 AOF2 AKR1B1
GZMK PACSIN1 MTA1
LTK FYN UXT
KLRB1 DYRK2 RPL18
TNFRSF25 LOC100133315 DDX28
CXCR3 GPRASP1 SRP46
STMN3 EIF3S7
ATP1A1 MYBL1
PSBP PABPC1
UBE2I AES
LGR6 RPLP2
TC2N FBL
GPR183 RPS19
CSNK1E
ARIH2
PUF60
FBXO21
F5
SAID, systemic autoimmune disease.
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signaling. These results suggest that alterations in
expression of a limited number of genes may, in turn,
influence the dysregulation of numerous integrated
immune response and inflammatory pathways that are
common to several SAIDs.
RQ-PCR validation
RQ of differential gene expression among disease-discor-
dant twin pairs and unrelated, matched controls was
independently evaluated by RT-PCR analyses for several
genes of interest (KRTCAP2, MAP2K6, IL1RN, IFI27,
SYTL2, FYN, LTK, EIF2AK2, FCERA1, LGR6, DEFA4,
ANXA3, TNFAIP6, CEACAM6, and TNFSF10) as
detailed in Materials and methods. As summarized in
Table 3, 13 of the 15 genes evaluated by RQ-PCR
showed the same trend (that is, increased or decreased
levels of gene expression) as those observed from the
microarray analysis in comparisons of twin probands
and unrelated, matched controls. Moreover, the
observed magnitude of differential expression for these
genes was generally similar for these independent
microarray and RQ-PCR assays. An opposite trend of
differential expression was observed for the FYN gene
by these assays, although the magnitudes of differential
gene expression were small (approximately 1.2-fold). For
the LTK gene, RQ-PCR did not detect a difference in
gene expression between probands and unrelated,
matched controls whereas microarray analysis estimated
a 2.3-fold increase in gene expression. Similar compara-
tive analyses of unaffected twins demonstrated inter-
mediate levels of differential gene expression versus
unrelated, matched controls for the majority of genes
surveyed.
Discussion
Pathology in human autoimmune diseases is thought to
result from a complex interplay of multiple, often poly-
morphic, genetic loci and accumulating environmental
exposures. The importance of genetic predisposition is
evidenced by high disease concordance rates and genetic
linkage analyses among family members [23,24]. Further
evidence for the role of genetics in SAID comes from
the identification of candidate susceptibility loci, espe-
cially genes encoding polymorphic variants of HLA class
II antigen-presenting molecules [25]. These findings are
supported by single-nucleotide polymorphism-based
genome-wide association studies (GWASs) identifying
large numbers of putative susceptibility markers
Figure 1 Heat map representing an unsupervised, hierarchical cluster analysis of the three study groups. The groups consisted of 20
probands with a systemic autoimmune disease, their 20 unaffected twins, and 40 unrelated, matched controls, respectively. The heat map uses
104 oligo probes that exhibited statistically significant differential gene expression (multiple comparison-adjusted P values (false discovery rate) of
less than 0.1) between probands and unrelated, matched controls. Color codes to the immediate right of the dendrogram correspond to
probands (yellow), unaffected twins (orange), and unrelated, matched controls (blue). The first major partition in the dendrogram (branches 1
and 2) is marked to the left of the heat map.
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positioned along multiple chromosomes [26]. Many of
the confirmed GWAS disease markers map in close
proximity to or within genes controlling immune
response signaling pathways (PTPN22, TNFAIP3,
TRAF1, CD40, and REL), transcriptional activation
(STAT4 and IRF5), and cytokine production (IL-12 and
IL-23) [26,27]. Interestingly, the majority of these disease
susceptibility loci individually confer only modest dis-
ease risks (relative risk values of 1.2 to 1.5) [28]. More-
over, many genetic risk factors are shared among
multiple autoimmune diseases (for example, SLE, RA,
type 1 diabetes, and multiple sclerosis) and across differ-
ent ethnic backgrounds, suggesting that the dysregula-
tion of fundamental immune regulatory pathways
underlies shared pathogenetic mechanisms [2,4,29].
We used RNA microarrays to measure differential
gene expression among MZ twins discordant for SAID
and unrelated, healthy controls matched on age, gender,
and ethnicity. Gene expression levels may be influenced
by subjects’ genetic background, age, gender, and
environmental exposures as well as by many experimen-
tal variables relating to clinical sampling, processing,
and data analysis. Despite these potential confounders,
an array-based study of peripheral blood cells from MZ
twins demonstrated significantly less variation in the
proportion of differentially expressed genes among twins
affected with an SAID (<2%) compared with unrelated
controls (>14%) [1]. Interestingly, MZ twin-derived lym-
phoblastoid cell lines exhibit near identical patterns of
monoallelic expression from otherwise heterozygous,
polymorphic loci, suggesting, at least in part, a role for
shared genetic controls of transcription or genetic
imprinting or both [30]. Unexpectedly, we did not detect
any significant differences in gene expression among
disease-discordant MZ twins in our study after correc-
tion for multiple comparisons. Similar profiles of gene
expression were described for array analyses examining
eight pairs of MZ twins discordant for multiple sclerosis,
in which investigators found only a single gene, IFN
alpha-inducible protein GIP3, differentially expressed in
Figure 2 Principal component analysis of the three study groups. The groups consisted of 20 probands with a systemic autoimmune
disease (green), their 20 unaffected twins (blue), or 40 unrelated, matched controls (red), respectively. The analysis uses 104 oligo probes that
exhibited statistically significant differential gene expression (multiple comparison-adjusted P values (false discovery rate) of less than 0.1)
between probands and unrelated, matched controls. C, unrelated, matched control; P, proband; PC, principal component; U, unaffected twin.
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over half of the eight twin pairs [5]. In contrast, larger
numbers of differentially expressed genes were identified
from lymphoblastoid cell lines derived from 11 MZ twin
pairs discordant for RA, although this analysis was not
adjusted for multiple comparisons [31]. Curiously, similar
patterns of differential gene expression have been observed
among SAID patients and their healthy, first-degree rela-
tives [2,23]. Collectively, these data support a role for both
genetic and other non-genetic variables, including perhaps
environmental exposures influencing disease development.
Also, small changes in levels of differential gene expression
(generally 1.2- to 2.5-fold variations) may not be statisti-
cally observable in studies of smaller numbers of twin
pairs, including our present study.
For 84 out of 104 probes (81%) with statistically signif-
icant differential expression between twins with an SAID
and unrelated, matched controls, we observed that gene
expression values of unaffected twins are positioned
between affected twins and unrelated controls, suggest-
ing that unaffected twins may represent an intermediate
or transitional state of disease development. Together,
our results and previous studies of MZ twins argue for
the importance of shared genetic determinants in regu-
lating gene expression profiles. However, additional fac-
tors, including epigenetic modifications that accumulate
in an age-dependent fashion (that is, epigenetic drift) as
well as accumulating environmental exposures, may also
influence asymmetric patterns of disease development
among MZ twins [32,33]. Differential patterns of gene
expression between the affected probands and unrelated
controls could reflect either acquired modifications that
were present before the onset of disease and could (to
Figure 3 Ingenuity pathways analysis of 104 probes with false discovery rate-adjusted P values of less than 0.1. The analysis compares
20 twins affected with systemic autoimmune disease and 40 unrelated, matched controls. P values (blue bars) describing the confidence of the
association of the data set with a given pathway are shown on the left vertical axis (-log(P value)). The cutoff threshold value (defined as P =
0.05) is also shown (horizontal yellow line). The ratio of the number of genes from the data set that map to a given pathway divided by the
total number of molecules that comprise the pathway (orange line connecting blue bars) is shown on the right vertical axis. IL-6, interleukin-6;
NF-B, nuclear factor-kappa-B.
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some extent) have conferred susceptibility to developing
an SAID or phenotypic features of the syndrome itself,
having less to do with disease etiology.
Heterogeneous phenotypes characterize the spec-
trum of clinical entities comprising SAID (for exam-
ple, SLE, RA, and IIM). However, as a group, these
diseases share many clinical, laboratory, genetic, auto-
antibody, and possibly pathogenetic features [34]. In
fact, many patients present clinically with overlap syn-
dromes sharing diagnostic criteria for multiple auto-
immune diseases. Previous microarray studies of
peripheral blood cells isolated from patients with four
different autoimmune diagnoses (SLE, RA, multiple
sclerosis, and insulin-dependent diabetes mellitus)
were found to have similar profiles of differential gene
expression relative to unrelated, healthy controls [4,6].
Moreover, a meta-analysis of gene expression array
profiles demonstrated high concordance between SLE
and RA, further emphasizing disease similarities [7].
Although our power to detect differences was limited,
our data indirectly support these conclusions in that
we were unable to detect significant differences in
gene expression among SAID subtypes (six with (J)
SLE, six with (J)RA, and eight with JIIM) by using
three independent statistical analyses (ANOVA,
mixed-effects models, and hierarchical clustering).
Together, these data suggest that shared alterations in
gene expression may underlie similar pathogenic
mechanisms among different SAIDs.
Our findings have corroborated previous studies iden-
tifying upregulation of type I IFN response genes
observed predominantly in SLE but also in RA and IIM
[7,10,12,14,16,19,35,36]. In fact, altered expression of
IFN-inducible genes has been correlated with disease
activity in SLE and IIM (DM and polymyositis) patients
undergoing therapy [13,17,36]. We likewise observed
upregulation of several SLE-associated IFN response
genes, including OASL (2.2-fold), PLSCR1 (2.3-fold),
EIF2AK2 (2.4-fold), and IFI27, the last of which exhib-
ited the highest degree of increased gene expression
(7.2-fold) in our study. Moreover, our findings are con-
sistent with a report of IFN response-associated gene
expression in DM whereby factors TNFAIP6, TNFSF10,
OASF, PLSCR1, EIF2AK2, and IFI27 were elevated in
peripheral blood [16].
Our study has several limitations, including small sam-
ple sizes and limited statistical power, resulting from the
challenges of identifying and recruiting qualified MZ
twins discordant for SAID. Studies of MZ twins, how-
ever, help to mitigate confounding factors associated
with genetic polymorphisms in studies of unrelated
human subjects. Variations in peripheral blood cell com-
position, disease activity, and effects of immunosuppres-
sive therapies may also present difficulties; however,
statistical evaluations of these variables did not reveal
evidence of effects on gene expression patterns. Metho-
dological and other technical variables were evaluated in
part by the use of independent RQ-PCR assays, which
corroborated our microarray data for the majority of
genes studied. Other limitations included the phenotypic
heterogeneity of the SAIDs studied and variations in
environmental exposure histories. Despite these vari-
ables, many of the differentially expressed genes and
candidate molecular pathways identified in our study are
consistent with findings reported in other studies of
SAID [7,12-14,16,36]. Functional analysis of genes found
differentially expressed in our SAID probands identified
multiple immunoregulatory (NF-B, IL-6, and apoptosis)
and proinflammatory (acute-phase response and Toll-
like receptor) pathways. Moreover, several of these
genes (for example, MAP2K6, EIF2AK2, and IL1RN)
have coordinated functions in the integration of multi-
ple, non-mutually exclusive regulatory pathways that
together may contribute to common features of the
SAID phenotype. The functional implications of each of
these pathways in autoimmune disease were reviewed
recently [37].
Conclusions
Gene expression profiling of biofluids and tissues from
SAID patients and matched controls has provided a
wealth of information into possible mechanisms of dis-
ease development, chronicity, and therapeutic response.
Table 3 Comparison of differential gene expression
values determined by relative quantitative-polymerase
chain reaction and microarray analyses
Gene RQ-PCRa Microarraya
Affected Unaffected Affected Unaffected
TNFAIP6 3.04 2.17 2.24 2.15
TNFSF10 1.50 1.37 1.58 1.33
MAP2K6 1.20 1.20 1.38 1.21
IL1RN 1.37 1.21 1.67 1.17
IFI27 1.20 2.01 7.24 6.21
ANXA3 3.18 1.82 2.79 2.43
CEACAM6 5.70 1.15 4.70 1.10
DEFA4 7.01 1.47 2.32 1.18
EIF2AK2 2.20 1.12 2.36 1.70
FCERA1 -1.82 -1.48 -1.76 -1.22
SYTL2 -1.93 -1.61 -1.49 -1.10
LGR6 -1.25 -1.13 -1.64 -1.11
KRTCAP2 -1.20 -1.20 -1.16 -1.07
LTK 1.02 1.21 2.32 1.06
FYN 1.23 1.19 -1.26 -1.01
aFold change values indicating increased (positive value) or decreased
(negative value) levels of gene expression in systemic autoimmune disease-
affected or -unaffected twins compared with unrelated, matched controls. RQ-
PCR, relative quantitative-polymerase chain reaction.
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Despite the variability of data anticipated with human
clinical studies, some meaningful consensus has
emerged [4,8]. As expected, we observed different gene
expression profiles between disease probands and unre-
lated controls. Our identification of an SAID-associated
profile of genes influencing multiple molecular path-
ways, including the immune response, cellular signaling,
inflammation, transcriptional/translational, and other
regulatory controls, is consistent with GWASs demon-
strating large numbers of genetic susceptibility loci, each
of which contributes only a modest degree of overall
risk [26,28,29]. Moreover, the lack of statistically signifi-
cant differences in gene expression detected between
affected and unaffected twins emphasizes the impor-
tance of genetic susceptibility to disease whereby unaf-
fected twins may represent a transitional state between
health and disease. Our report of shared profiles of
altered gene expression among SAID patients with dif-
ferent clinical phenotypes is consistent with the hypoth-
esis that many SAIDs have common features of disease
pathogenesis. The identification of relevant genes whose
products regulate and integrate multiple physiologic
pathways might permit the development of targeted
therapeutics benefiting a broader spectrum of patients
with multiple SAID phenotypes.
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